Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT06318273 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06318273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06318273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 8, 2024
Completion date
May 31, 2027
Enrollment
152 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer